Recombinant Anti-CTLA4 x Anti-GLUT2 Bispecific Antibody (scFv-Fc) (BSCFV-145)

Recombinant Anti-CTLA4 x Anti-GLUT2 Bispecific Antibody (scFv-Fc) is formed by fusing two different scFv fragments to the hinge and Fc regions, in which the Fc region are engineered by KIH. Two of scFv moiety has the antibody variable domain of either anti-CTLA4 specificity or anti-GLUT2 specificity, which produces bivalent IgG-like molecules with desired characteristics of intact antibodies. This BsAb can bind two factors simultaneously. It is designed for the research of Renal cell cancer (RCC) therapy.

Datasheet INQUIRY

Specifications

Targets

CTLA4 & GLUT2

Type

scFv-based Bispecific Fragments

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Renal cell cancer (RCC)

Targets

Target 1

CTLA4

Gene ID

1493

UniProt ID

P16410

Alternative Names

CTLA4; cytotoxic T-lymphocyte-associated protein 4; CD; GSE; GRD4; ALPS5; CD152; CTLA-4; IDDM12; CELIAC3; cytotoxic T-lymphocyte protein 4; CD152 isoform; celiac disease 3; insulin-dependent diabetes mellitus 12; cytotoxic T-lymphocyte-associated serine esterase-4; cytotoxic T lymphocyte associated antigen 4 short spliced form; ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4

Target 2

GLUT2

Gene ID

6514

UniProt ID

P11168

Alternative Names

SLC2A2; solute carrier family 2 (facilitated glucose transporter), member 2; GLUT2; solute carrier family 2, facilitated glucose transporter member 2; glucose transporter type 2, liver

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CTLA4 x Anti-GLUT2 Bispecific Antibody (scFv-Fc) (BSCFV-145). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CTLA4 x Anti-GLUT2 Bispecific Antibody (scFv-Fc) (CAT#: BSCFV-145)

Specifications

Targets

Customer Reviews and Q&As